AstraZeneca PLC (AZN)vsOncology Institute Inc (TOI)
AZN
AstraZeneca PLC
$185.95
+0.81%
HEALTHCARE · Cap: $282.69B
TOI
Oncology Institute Inc
$4.87
+2.74%
HEALTHCARE · Cap: $523.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 10974% more annual revenue ($60.44B vs $545.76M). AZN leads profitability with a 17.2% profit margin vs -8.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-8.7%
Fair Value
$2.41
Current Price
$4.87
$2.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a mature stock while TOI is a hypergrowth play — different risk/reward profiles.
TOI carries more volatility with a beta of 0.41 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 45/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a premier healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment methodologies. The company leverages advanced technologies and personalized care strategies to enhance patient outcomes, while also prioritizing clinical trials and collaborations with leading research institutions. As the demand for advanced cancer therapies grows, TOI is strategically positioned to capitalize on this market trend, underpinned by a robust pipeline and a deep reservoir of oncology expertise, making it an attractive investment opportunity in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?